8-K filings in May 2024, explained

Roivant unit Dermavant renegotiates debt, cutting potential cash payments by over $300 million

On May 24, 2024, Roivant subsidiary Dermavant Sciences Ltd. entered into agreements to renegotiate its debt, which the filing says would reduce potential cash payments by over $300 million in aggregate. Roivant will contribute $195 million in preferred equity to Dermavant, and the royalty purchasers and NovaQuest receive about 13.2% of Dermavant's shares, leaving Roivant with about 87% of common and preferred shares after closing. For shareholders, the deal lowers future cash obligations but dilutes Roivant's stake in Dermavant and raises the interest rate on one credit agreement.

• Debt Renegotiation expected to reduce potential cash payments by over $300 million in aggregate, with about $225 million achieved over the next three fiscal years.
• Roivant to contribute $195 million to Dermavant for convertible preferred shares with a liquidation preference of 1.5 times invested capital.
• Credit Agreement maturity extended from May 2026 to May 2028, with the interest rate rising from 10% to 12.25% per annum.
• NovaQuest eliminates fixed quarterly payments totaling $176.3 million and milestone payments of up to $141.0 million; remaining payments of $122.5 million run through March 31, 2029.